开窗Anaconda内移植物治疗复杂腹主动脉瘤的国际多中心结局
技术成功率88.4%,术中IA型内漏6.9%但多数自愈,1年和3年免于AAA增长分别为97.9%和86.4%,靶血管通畅率分别为96.4%和92.7%。
要点
- 开窗Anaconda治疗复杂AAA技术成功率88.4%,术中IA型内漏6.9%但82.6%早期自愈。
- 1年和3年免于AAA增长分别为97.9%和86.4%,免于破裂分别为99.7%和99.1%。
- 1年和3年靶血管通畅率分别为96.4%和92.7%,再干预率19.1%。
核心结论
- 定制开窗Anaconda内移植物是治疗复杂腹主动脉瘤的有价值选择。
- 术中IA型内漏相对常见,但多数病例可自发消退。
研究设计与样本
- 纳入中心需治疗超过15例复杂AAA或IV型胸腹主动脉瘤患者。
- 患者包括短颈肾下型98例、近肾型191例、肾上型27例、IV型胸腹主动脉瘤19例;平均年龄73.6±4.6岁,男性292例。
主要发现
- 技术成功率为88.4%(初次82.7%,辅助初次5.7%)。
- 术中IA型内漏发生率为6.9%,其中82.6%在早期随访中自发消失。
- 1年和3年免于AAA增长分别为97.9±0.9%(n=190)和86.4±3.0%(n=68),免于破裂分别为99.7±0.3%(n=191)和99.1±0.7%(n=68)。
关键数值与推荐
- 1年和3年无内漏生存(排除自发消退的术中内漏)分别为73.4±2.6%(n=143)和65.6±3.4%(n=45)。
- 1年和3年靶血管通畅率分别为96.4±0.7%(n=493)和92.7±1.4%(n=156)。
- 64例(19.1%)共接受75次再干预,其中25例因内漏;1年和3年免于再干预生存分别为83.6±2.2%(n=190)和71.0±3.7%(n=68)。
- 围手术期及术后24小时内无死亡;30天内死亡14例(4.2%),随访期间死亡39例(11.6%),其中3例归因于AAA(1例破裂、1例移植物感染、1例双侧肾动脉闭塞)。
- 1年和3年估计累积生存率分别为89.8±1.8%(n=191)和79.2±3.0%(n=68)。
临床怎么用
- 对于复杂腹主动脉瘤(短颈、近肾、肾上型或IV型胸腹主动脉瘤),开窗Anaconda内移植物可作为治疗选项。
- 术后需密切监测IA型内漏,尤其是存在大颈角、三开窗或近端加固环等关联因素时。
- 需关注肾功能变化,平均eGFR在随访中下降。
- 再干预率约19.1%,需长期随访监测内漏和靶血管通畅情况。
局限性
- 回顾性病例系列设计,非随机对照。
- 中位随访仅1.2年(IQR 0.4-2.6),长期结局数据有限。
- 仅纳入治疗超过15例的中心,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To date, information on the fenestrated Anaconda endograft is limited to case series with a small sample size. This study was performed to assess the technical and clinical outcome of this device in a large international case series. METHODS: All worldwide centers having treated more than 15 complex abdominal aortic aneurysms (AAA) or type IV thoracoabdominal aortic aneurysm patients with the fenestrated Anaconda endograft were approached. Main outcome parameters were procedural technical success, postoperative and follow-up clinical outcome for endoleaks, target vessel patency, reintervention rate, and patient survival. RESULTS: Three hundred thirty-five consecutive cases treated between June 2010 and May 2018 in 11 sites were included. Patients were treated for a short neck infrarenal (n = 98), juxtarenal (n = 191), suprarenal AAA (n = 27), or type IV thoracoabdominal aortic aneurysm (n = 19). Mean age was 73.6 ± 4.6 years (292 male). Endografts contained a total of 920 fenestrations, with a mean of 2.7 ± 0.8 fenestrations per case. Technical success was 88.4% (primary, 82.7%; assisted primary 5.7%). In 6.9% of cases, a procedural type IA endoleak was observed, spontaneously disappearing in 82.6% during early follow-up. The development of a type IA endoleak was associated with greater neck angulation (odds ratio [OR], 0.94; P = .01), three fenestrations (OR, 42.7; P = .01) and the presence of augmented proximal rings (OR, 0.17; P = .03). Median follow-up was 1.2 years (interquartile range, 0.4-2.6). The mean estimated glomerular filtration rate deteriorated from 67.6 ± 19.3 mL/min/1.73 m2 preoperatively to 59.3 ± 22.7 mL/min/1.73 m2 at latest follow-up (P = .00). The freedom from AAA growth were 97.9 ± 0.9% (n = 190) and 86.4 ± 3.0% (n = 68), with a freedom from AAA rupture of 99.7 ± 0.3% (n = 191) and 99.1 ± 0.7% (n = 68), at 1 and 3 years, respectively. The endoleak-free survival, excluding spontaneously resolved procedural endoleaks, at 1 and 3 years was 73.4 ± 2.6 (n = 143) and 65.6 ± 3.4% (n = 45), respectively. The target vessel patency at one and three years were 96.4 ± 0.7% (n = 493) and 92.7 ± 1.4% (n = 156), respectively. A total of 75 reinterventions were done in 64 cases (19.1%), of which 25 cases for an endoleak. The reintervention-free survival at 1 and 3 years were 83.6 ± 2.2% (n = 190) and 71.0 ± 3.7% (n = 68), respectively. No deaths during procedure, extending within 24 hours postoperatively, were observed. Within 30 days 14 patients (4.2%) died and during follow-up another 39 patients (11.6%) died. Three deaths were considered AAA related (one rupture, one endograft infection, and one bilateral renal artery occlusion). The estimated cumulative survival at 1 and 3 years were 89.8 ± 1.8% (n = 191) and 79.2 ± 3.0% (n = 68), respectively. CONCLUSIONS: The custom-made fenestrated Anaconda endograft is a valuable option for the treatment of a complex AAA. A procedural type IA endoleak is seen relatively frequently, but spontaneously resolves in most cases.
引用
- de Niet A, Zeebregts CJ, Reijnen MMPJ, et al. Outcomes after treatment of complex aortic abdominal aneurysms with the fenestrated Anaconda endograft. J Vasc Surg. 2019. PMID: 31831315. doi:10.1016/j.jvs.2019.08.283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。